Clinical Trial Detail

NCT ID NCT03506802
Title TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements no
Sponsors Jonsson Comprehensive Cancer Center
Indications

multiple myeloma

Therapies

Filgrastim + Plerixafor

Lenalidomide

Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC

Melphalan

Age Groups: senior adult

No variant requirements are available.